Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
646 clinical trials found
Clinical trials

COLLIGO

mavaCamten Observational evidence Global cOnsortium in HCM [COLLIGO-HCM] (NCT06372457)

The aim of this study is to investigate treatments and real-world effectiveness for hypertrophic cardiomyopathy (HCM), including examining the path to diagnosis, disease progression, and the new treatment for obstructive HCM (o-HCM), mavacamten. This protocol localisation for COLLIGO-HCM is for The Alfred Hospital participating site in Australia. It will address only a subset of the objectives from the master protocol which were deemed applicable after conducting feasibility.

No longer recruiting

COMB157GAU01

Secondary use of data study characterizing Kesimpta (ofatumumab) onboarding and utilization in RMS patients using MSGo, with a non-interventional primary use of data sub-study comparing Patient Reported Outcomes relative to Clinical Outcomes (EAFToS) (NCT05090033)

No longer recruiting

CORE

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (NCT05079919)

No longer recruiting

CorSky

BIO|CONCEPT.CorSky Family (NCT05610176)

No longer recruiting

CorWave

A Clinical Study of the CorWave® Left Ventricular Assist System For the treatment of patients with advanced heart failure (NCT06907017)

The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients. Trial aim: implantation and use of the CorWave LVAS to evaluate the safety and effectiveness of the CorWave LVAD to treat advanced left ventricular heart failure.
Currently recruiting

COSEAL

Effect of Coseal at the time of durable left ventricular assist device implantation on orthotopic heart transplantation (ACTRN12625000599471)

Durable left ventricular assist device (LVAD) is a form of mechanical support used in patients with end-stage heart failure as a bridge to heart transplantation. The technical challenges in heart transplantation in patients with an LVAD are often associated with adhesions around the heart and great vessels. This can lead to an increase in the surgical time, use of blood products, and overall perioperative risk. Coseal is a commercially available product which forms a hydrogel that inhibits adhesion formation. This has been studied in many surgical procedures including cardiac surgery, but has not been thoroughly studied in this population. This study aims to investigate the effect of Coseal spray application at the time of LVAD implant on the adhesions that are encountered at the time of orthotopic heart transplantation (OHTx).
Coming soon

COSTAR

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in With Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti-PD(L)1 Therapy and Chemotherapy (NCT04655976)

No longer recruiting

CP-AU-007-01

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer (NCT05267626)

Currently recruiting

CP-MVC-101-01

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer (NCT04844073)

Currently recruiting

CPHE885B12201

A Phase 2 Study of PHE885, a BCMA-directed CAR-T Cell Therapy for Patients with Relapsed and Refractory Multiple Myeloma (NCT05172596)

Currently recruiting

CROSSING

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) (NCT05583227)

Currently recruiting

CRSP-ONC-006

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (NCT05643742)

Currently recruiting

CRSP-ONC-LTF

A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies (NCT06208878)

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies.
Coming soon

CRVOMed Study

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery after Ischemic Stroke (NCT06987643)

Currently recruiting

CS2009

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors (NCT06741644)

Currently recruiting

CSL TAP

A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex® ]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleeding (NCT05568888)

No longer recruiting

CSL222_3005

Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 [Etranacogene Dezaparvovec] Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies (NCT06003387)

Currently recruiting

CSL312-3002

An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)

No longer recruiting

CT LEFT MAIN

The role of CT Angiography as a suitable alternative to Invasive Coronary Angiography in detecting Left Main Restenosis (Trial Not Registered)

No longer recruiting

CVAY736I12301 - VAYHIT1

A phase 3, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) (NCT05653349)

Currently recruiting
8 9 10 11 12